Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemia

J Natl Cancer Inst. 2008 Jul 2;100(13):908-9. doi: 10.1093/jnci/djn204. Epub 2008 Jun 24.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / drug therapy
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / enzymology
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / genetics
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / metabolism*
  • Piperazines / pharmacology*
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines / pharmacology*
  • Pyrimidines / therapeutic use
  • Signal Transduction / drug effects
  • src-Family Kinases / metabolism*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • lyn protein-tyrosine kinase
  • src-Family Kinases